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he nuclear structures that contain symmetrical dimeth-
 
ylated arginine (sDMA)–modiﬁed proteins and the role
of this posttranslational modiﬁcation is unknown.
Here we report that the Cajal body is a major epitope in
HeLa cells for an sDMA-speciﬁc antibody and that coilin is
an sDMA-containing protein as analyzed by using the
sDMA-speciﬁc antibody and matrix-assisted laser desorption
ionization time of ﬂight mass spectrometry. The methyla-
tion inhibitor 5
 
 
 
-deoxy-5
 
 
 
-methylthioadenosine reduces the
levels of coilin methylation and causes the appearance of
SMN-positive gems. In cells devoid of Cajal bodies, such
as primary ﬁbroblasts, sDMA-containing proteins concen-
T
 
trated in speckles. Cells from a patient with spinal muscular
atrophy, containing low levels of the methyl-binding protein
SMN, localized sDMA-containing proteins in the nucleo-
plasm as a discrete granular pattern. Splicing reactions are
efﬁciently inhibited by using the sDMA-speciﬁc antibody or
by using hypomethylated nuclear extracts, showing that active
spliceosomes contain sDMA polypeptides and suggesting
that arginine methylation is important for efﬁcient pre-
mRNA splicing. Our ﬁndings support a model in which ar-
ginine methylation is important for the localization of coi-
lin and SMN in Cajal bodies.
 
Introduction
 
Protein arginine methylation is a posttranslational modification
that results in the mono- and dimethylation of the guanidino
nitrogen atoms of arginine (Gary and Clarke, 1998). Arginines
can be dimethylated either in a symmetrical or asymmetrical
manner (symmetrical dimethylated arginine [sDMA]* and
asymmetrical dimethylated arginine [aDMA]). Three of the
six identified protein arginine methyltransferases (PRMT1,
PRMT5, and PRMT6) catalyze the formation of dimethylated
arginines in glycine- and arginine-rich regions (GARs) (Gary
and Clarke, 1998; Frankel et al., 2001). The two major
groups of proteins that contain aDMA include RNA-binding
proteins and histones (McBride and Silver, 2001). Asym-
metrical dimethylation of arginines has been shown to influence
nuclear export (Lee et al., 1996), nuclear import (Xu et al.,
2001), protein–protein interactions (Bedford et al., 2000),
and transcription (Chen et al., 1999; Yun and Fu, 2000;
Mowen et al., 2001; Wang et al., 2001). In contrast, much
less is known about the role of sDMAs in cellular pro-
cesses. PRMT5, the only known PRMT to catalyze sDMA
(Branscombe et al., 2001), has been shown to methylate myelin
basic protein (MBP) and histones on arginines in vitro (Pollack
et al., 1999). PRMT5 resides in a cytoplasmic 20S complex
with pICln and also has methyltransferase activity toward
SmB, B
 
 
 
, D1, and D3 proteins (Brahms et al., 2001; Friesen
et al., 2001b; Meister et al., 2001b). MBP, SmB, B
 
 
 
, D1, and
D3, and the Sm-like protein LSm4 are the only known proteins
that contain sDMAs in vivo (Baldwin and Carnegie, 1971;
Brahms et al., 2000, 2001).
The cellular localization of sDMA-containing proteins is un-
known, but these proteins have been proposed to be imported
 
Address correspondence to Stéphane Richard, Lady Davis Institute, 3755
Côte Ste-Catherine Rd., Montréal, Québec, Canada H3T 1E2. Tel.: (514)
340-8260. Fax: (514) 340-8295. E-mail: stephane.richard@mcgill.ca
F.M. Boisvert and J. Côté contributed equally to this work.
*Abbreviations used in this paper: aDMA, asymmetrical dimethylated ar-
ginine; AdML, adenovirus major late; GAR, glycine- and arginine-rich
region;
 
 
 
IGC, interchromatin granule cluster; MALDI-TOF, matrix-assisted
laser desorption ionization time of flight; MBP, myelin basic protein;
MTA, 5
 
 
 
-deoxy-5
 
 
 
-methylthioadenosine; NRP, ribonucleoprotein;
sDMA, symmetrical dimethylated arginine; siRNA, small interfering
RNA;
 
 
 
SMA, spinal muscular atrophy.
Key words: PRMT5; Cajal; SMN; arginine methylation; splicing 
958 The Journal of Cell Biology 
 
|
 
 
 
Volume 159, Number 6, 2002
 
within the nucleus by a complex that contains the sDMA-
binding protein, SMN (Friesen et al., 2001a). SMN is the
protein product of the survival of motor neurons gene
(
 
SMN1
 
) responsible for spinal muscular atrophy (SMA)
(Lefebvre et al., 1995). SMA is an autosomal recessive neu-
rodegenerative disease, which is characterized at the clinical
level by degeneration and loss of spinal cord motor neurons
resulting in muscular weakness and atrophy (Melki, 1997).
Patients with SMA have a marked decrease in the levels of
SMN protein (Burghes, 1997; Coovert et al., 1997) and
contain mutations that disrupt associations with its arginine
glycine-rich–binding partners (Pellizzoni et al., 1999). SMN
protein complexes function in the assembly of various ribo-
nucleoprotein (RNP) complexes including U snRNPs (Fi-
scher et al., 1997; Pellizzoni et al., 1998; Meister et al.,
2001a). The role of arginine methylation in the process of
RNP complex assembly is unknown, but it is thought to be
one of the signals for targeting to the SMN complexes (Frie-
sen et al., 2001b; Meister et al., 2001b).
The nucleus contains many dynamic nuclear structures,
including Cajal (coiled) bodies, gems, interchromatin gran-
ule clusters (IGCs), the perinucleolar compartment, PML
bodies, Sam68 nuclear bodies, and the nucleolus (Lamond
and Earnshaw, 1998; Matera, 1999; Gall, 2000; Spector,
2001). Although the function of the Cajal body remains un-
known, there is considerable evidence suggesting that it may
be involved in snRNP maturation/biogenesis, histone pre-
mRNA processing, and the assembly of the transcriptosomes
(Matera, 1999; Gall, 2000). The Cajal body contains many
components including coilin (the marker of Cajal bodies
[Andrade et al., 1993]), snRNPs (Eliceiri and Ryerse, 1984;
Fakan et al., 1984), and SMN (Liu and Dreyfuss, 1996; Pel-
lizzoni et al., 1998). Cajal bodies have a twin structure called
gems that contain SMN complexes but not snRNPs or coilin
(Liu and Dreyfuss, 1996). It is not known why only a subset
of cells contain gems. Coilin associates with SMN and re-
quires its arginine glycine–rich regions (Hebert et al., 2001).
Herein we show that Cajal bodies are rich in sDMA-con-
taining proteins in HeLa cells and that coilin is a methylated
protein. In primary cells devoid of Cajal bodies, sDMA pro-
teins stained nuclear speckles. Interestingly, in cells derived
from a patient with SMA, which express very low levels of
SMN, sDMA-containing proteins are located in a granular
pattern within the nucleus. Our results suggest that the lev-
els of the methyl-binding protein SMN may regulate the nu-
clear structures that are recognized by methyl-specific anti-
bodies in situ. Moreover, we show data suggesting that a
normal level of sDMA-containing proteins in the cells is im-
portant for pre-mRNA splicing.
 
Results
 
A novel anti-sDMA–specific antibody
 
Symmetrical dimethylation of arginines is a posttranslational
modification that has been described for MBPs (Baldwin
and Carnegie, 1971), the SmB, B
 
 
 
, D1, D3, and LSm4 pro-
teins (Brahms et al., 2000, 2001). To study the role of sym-
metrical dimethylated arginines, an sDMA-specific antibody
was generated by immunizing rabbits with a KLH-coupled
 
nonapeptide containing four sDMA-glycine repeats. The af-
finity-purified antibody, named SYM10, recognized pep-
tides corresponding to the COOH termini of Sm proteins
D1 and D3 containing sDMA (SmD1 and SmD3 sDMA
[Fig. 1 A]) and a generic RG-rich peptide containing sDMA
(GAR sDMA [Fig. 1 A]). The SYM10 antibody did not rec-
ognize nonmethylated peptides corresponding to SmD3,
GAR, and an unrelated RG-rich sequence (RG [Fig. 1 A]) or
peptides containing aDMA (GAR aDMA [unpublished
data; Fig. 1 A]). The SYM10 antibody had the strongest af-
finity for the immunizing peptide sym10
 
sDMA
 
. SYM10 did
not recognize a peptide from MBP that contained a unique
sDMA-glycine repeat (MBP sDMA [Fig. 1 A]). The fact
that SYM10 did not recognize the methylated MBP peptide
suggests that SYM10 requires more than one sDMA-G
dipeptide in a given polypeptide for binding. To better char-
acterize the epitope recognized by SYM10, we performed
ELISAs using a series of synthetic nonapeptides based on the
immunizing peptide (sym10) backbone (Fig. 1 B). Even at a
1:500 dilution, the SYM10 antibody did not show any reac-
tivity for the nonmethylated sym10 peptide or for a sym10
derivative containing only one sDMA residue (Fig. 1 B, as-
terisk and diamond, respectively). Interestingly, SYM10 re-
acted more strongly with a derivative harboring two spaced
sDMA-Gs than two contiguous sDMA-G dipeptides (Fig. 1
B, triangle and circle, respectively). This defines the SYM10
epitope as requiring at least two, preferentially noncontigu-
ous, sDMA-Gs in a given polypeptide sequence.
 
SYM10 recognizes many cellular proteins including 
coilin and the Sm proteins B, B’, and D
 
Immunoprecipitations were performed to identify the en-
dogenous proteins that contain sDMA at steady state. HeLa
cells were metabolically labeled with (
 
3
 
H-
 
methyl
 
)-
 
L
 
-methio-
nine in the presence of cycloheximide and chloramphenicol
for 3 h, an established assay to measure in vivo methylation
(Liu and Dreyfuss, 1995). Translational inhibitors were used
to ensure that incorporation of the (
 
3
 
H-
 
methyl
 
) group oc-
curred only as a result of methylation. Cells were lysed, and
immunoprecipitations were performed using the SYM10
antibody, the snRNP-specific antibody Y12 (Lerner et al.,
1981), or normal rabbit serum (Fig. 1 C). The bound pro-
teins were resolved by electrophoresis and visualized by fluo-
rography. SYM10 immunoprecipitated a pattern of methyl-
ated proteins that was similar but distinguishable from the
snRNP antibody Y12 (Fig. 1 C, lane 1 compared with 2).
Since SYM10 recognized methylated SmB
 
 
 
, B, and D pro-
teins, we examined whether SYM10 could immunoprecipi-
tate other unmethylated Sm proteins as part of a complex.
HeLa cells were metabolically labeled with 
 
35
 
S-methionine
and immunoprecipitated by using SYM10 or Y12. Both an-
tibodies immunoprecipitated the complete repertoire of Sm
proteins (Fig. 1 D). These findings imply that SYM10
recognizes methylated SmB
 
 
 
, B, and D in the context of ma-
ture snRNP complexes. SYM10 also immunoprecipitated a
unique pattern of higher molecular weight polypeptides that
was distinct from Y12 (Fig. 1 D). To determine which pro-
teins are recognized directly by SYM10, immunoblotting
was performed on HeLa total cell extracts (Fig. 1 E). As ex- 
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Figure 1. SYM10 recognizes many cellular proteins including coilin and the Sm proteins B, B’, and D. (A and B) The specificity of 
SYM10 was examined using an ELISA. The quantity of peptide is indicated on the abscissa and the absorbance on the ordinate. (C) 
HeLa cells were metabolically labeled with (methyl-
3H)-L-methionine in the presence of translation inhibitors, lysed, and immuno-
precipitated with the indicated antibodies. The 
3H-labeled proteins were visualized by fluorography. The migration of SmB, B’, and D 
proteins is indicated. (D) HeLa cells were metabolically labeled with [
35S]methionine, lysed, and immunoprecipitated with the SYM10 
antibody, Y12, or normal rabbit serum. Proteins were separated using high TEMED SDS-PAGE. The 
35S-labeled proteins were visualized 
by autoradiography. The migration of Sm proteins and U1A is indicated. (E) HeLa cell lysates were immunoblotted with the NRS or the 
SYM10 antibody (1:1,000). (F) The methylosome and SMN complexes are immunoprecipitated by SYM10. Immunoprecipitation was 
performed in HeLa cells using SYM10, and the proteins were immunoblotted with PRMT5, SMN, and Sm B/B’ (ANA128) antibodies. 
(G) Coilin is recognized directly by SYM10. Immunoprecipitation was performed in HeLa cells using  -coilin antibodies followed by 
immunoblotting with SYM10 (1:1,000; left). Coilin is immunoprecipitated by SYM10. Immunoprecipitation was performed with the 
SYM10 antibody using HeLa cells transfected with myc-coilin followed by immunoblotting with  -Myc antibodies to detect transfected 
myc-coilin (right). 
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pected, SYM10 recognized a doublet of 
 
 
 
30 kD and a band
of 
 
 
 
16 kD characteristic of Sm proteins B, B
 
 
 
, and D that
were not detected with normal rabbit serum (Fig. 1 E). Ma-
jor bands of apparent molecular weights of 95, 80, and 60
kD were also detected (Fig. 1 E). A longer exposure of a dif-
ferent SYM10 immunoblot demonstrated that many pro-
teins contain sDMA (Fig. 1 E, lane 4). The fact that SYM10
can directly recognize SmB/B
 
 
 
 proteins in which sDMAs are
found in a noncontiguous RG motif (Brahms et al., 2001) is
in good agreement with the SYM10 epitope mapped by
ELISA using synthetic peptides. The methylation of Sm
B/B
 
 
 
 and D proteins is thought to occur in a complex dubbed
the methylosome (Friesen et al., 2001b; Meister et al.,
2001b). The presence of Sm proteins, SMN, and PRMT5
in the SYM10 complex was confirmed by probing SYM10
immunoprecipitates with their respective antisera (Fig. 1 F,
lane 3). This shows that SYM10 can coimmunoprecipitate
components of the methylosome and the SMN complexes.
To identify other proteins recognized by the SYM10 anti-
body, a large scale immunoprecipitation was performed on
HeLa cells followed by a matrix-assisted laser desorption ion-
 
ization time of flight (MALDI-TOF) mass spectrometry
identification of the digested proteins. The protein with an
apparent molecular weight of 80 kD was identified as coilin
(gi:4758024; Table I). The proteins at 95 and 60 kD will be
described elsewhere. Coilin contains multiple repeated RG
motifs. The RG-rich regions of coilin are not known to be
methylated but have been shown to be required for SMN in-
teraction (Hebert et al., 2001). These RG-rich sequences are
clustered in two repeated motifs that are both potential
epitopes for SYM10. The peptides derived from coilin were
examined for the presence of dimethylated arginines (Table
I). Since methylation of arginines prevents cleavage by
trypsin (Baldwin and Carnegie, 1971), we predicted peptide
sizes that would result from the dimethylation of arginines in
coilin. Peptide GWGR
 
397
 
EENLFSWK contains two methyl
groups, indicating arginine 397 is dimethylated (Table I).
Peptide GAKGR
 
410
 
GMR
 
413
 
GR contains four methyls, indi-
cating that both arginines 410 and 413 are dimethylated.
The other peptide that is informative is GMR
 
413
 
GR
 
415
 
GR
that contains four methyl groups, indicating that both argi-
nines 413 and 415 are dimethylated. With the mass spectrom-
 
Table I. 
 
The SYM10 antibody immunoprecipitates coilin
Residues start–end Mass observed Mass expected Sequence Modifications
 
p80-coilin
1–8 864.43 864.42 MAASETVR
1–10 1133.55 1133.54 MAASETVRLR
83–88 773.43 773.43 VKLEER
132–136 713.36 713.35 HWKSR
145–151 813.48 813.47 VLDLEPK
182–186 615.36 615.35 RKSPK
196–201 685.41 685.4 KAKNPK
197–204 870.37 870.36 AKNPKSPK
264–274 1233.62 1233.61 VTLEARNSSEK
270–281 1332.61 1332.6 NSSEKLPTELSK
275–281 787.48 787.47 LPTELSK
288–297 1074.48 1074.52 NTTADKLAIK
394–405 1509.68 1537.75 GWGREENLFSWK 2 methyls
394–408 1765.98 1791.69 GWGREENLFSWKGAK 2 methyls
406–413 876.3 848.45 GAKGRGMR 2 methyls + oxidation (M)
406–415 1074.52 1046.25 GAKGRGMRGR 2 methyls
406–415 1102.55 1046.25 GAKGRGMRGR 4 methyls
406–415 1089.53 1061.58 GAKGRGMRGR 2 methyls + oxidation (M)
406–417 1314.26 1258.7 GAKGRGMRGRGR 4 methyls
409–417 1030.44 1002.55 GRGMRGRGR 2 methyls
409–417 1058.42 1002.55 GRGMRGRGR 4 methyls
409–417 1046.39 1018.54 GRGMRGRGR 2 methyls + oxidation (M)
409–417 1074.52 1018.54 GRGMRGRGR 4 methyls + oxidation (M)
411–417 805.41 805.4 GMRGRGR Oxidation (M)
411–417 861.28 805.42 GMRGRGR 4 methyls
411–419 1030.44 1002.55 GMRGRGRGR 2 methyls
411–419 1058.42 1002.55 GMRGRGRGR 4 methyls
411–419 1046.39 1018.54 GMRGRGRGR 2 methyls + oxidation (M)
411–419 1074.52 1018.54 GMRGRGRGR 4 methyls + oxidation (M)
430–435 720.38 720.38 STDNQR  
To identify proteins recognized by SYM10, a large scale immunoprecipitation was performed on HeLa cells followed by a MALDI-TOF mass spectrometry
identification of the tryptic-digested proteins. The protein with an 
 
M
 
r of 80 kD was identified as coilin (sequence data available from GenBank/EMBL/DDBJ
under accession no. 4758024). The peptides derived from coilin were examined for the presence of DMA. Since methylation of arginines prevents cleavage
by trypsin, peptide sizes that would result from the dimethylation of arginines in coilin were predicted. The table presents the residue numbers and the mass
observed and expected of peptides found using the MALDI-TOF. 
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etry data, we can only assess the methylation of arginine 397,
410, 413, and 415 by using trypsin. But it is likely that argi-
nines 417 and 419 are also dimethylated as this would pro-
vide epitopes for SYM10. Since the mass spectrometry iden-
tification does not distinguish between asymmetrical and
symmetrical methylation, anticoilin immunoprecipitations
were immunoblotted with the sDMA-specific SYM10 anti-
body (Fig. 1 G, left). A single band of 
 
 
 
80 kD could be de-
tected by SYM10 in the coilin immunoprecipitate (Fig. 1 G,
lane 3), indicating that coilin can indeed be recognized di-
rectly by SYM10 and thus contains sDMA. Finally, to con-
firm the mass spectrometry identification the reciprocal
coimmunoprecipitation experiment was performed on myc-
coilin–transfected cells (Fig. 1 G, right). As expected, myc-
coilin was observed in SYM10 immunoprecipitates (Fig. 1 G,
lane 6). Together, these results demonstrate that coilin is an
sDMA-containing protein in vivo.
PRMT5 is the only methyltransferase known to generate
sDMAs (Branscombe et al., 2001), and we have shown that
it is present in SYM10 immunoprecipitates (Fig. 1 F). It is
thus inferred that PRMT5 would be the enzyme responsible
for producing the SYM10 epitopes. To verify this hypothe-
sis, we made use of a small interfering RNA (siRNA) ap-
proach to knock-down PRMT5 expression in vivo. A con-
trol siRNA or an siRNA engineered to specifically target
PRMT5 mRNA was introduced in Jurkat cells using elec-
troporation. Cell extracts were prepared 72 h posttransfec-
tion, and the levels of PRMT5 protein was assessed by im-
munoblotting (Fig. 2). Introducing 60 to 240 pmoles of
control siRNA had no effect on PRMT5 protein levels (Fig.
2, middle, lanes 1–3). In contrast, the same amounts of
siRNA directed against PRMT5 produced a gradual de-
crease in PRMT5 protein level (Fig. 2, middle, lanes 4–6).
Strikingly, a similar decrease is observed in the SYM10
immunoblot signal (Fig. 2, top, lanes 4–6). Equivalent
amounts of total proteins was present in each lane as assessed
by antiactin immunoblotting (Fig. 2, bottom). These results
suggest that PRMT5 is one of the enzymes responsible for
generating SYM10 epitopes, including the ones found in Sm
proteins B/B
 
 
 
 and D, coilin, p60, and p95.
 
sDMA-containing proteins are nuclear 
and concentrated in nuclear foci
 
The cellular distribution of sDMA-containing proteins was
examined by indirect immunofluorescence using the SYM10
antibody in HeLa cells. SYM10 stained bright foci and the
Figure 2. Down-regulation of PRMT5 by siRNA results in a loss of 
recognized proteins by SYM10. Control siRNAs (lane 1–3) or siRNAs 
engineered to specifically target PRMT5 mRNAs (lane 4–6) were 
introduced in Jurkat cells using electroporation. Cell extracts were 
prepared 72 h posttransfection, and the levels of SYM10 (top), PRMT5 
(middle), and actin (bottom) were assessed by immunoblotting.
Figure 3. Nuclear bright foci stained with SYM10. HeLa cells 
treated with DMSO ( MTA) or the methylation inhibitor MTA 
( MTA) for 24h were labeled for immunofluorescence using 
SYM10 (A and B) and the snRNP antibody Y12 (C and D). A peptide 
competition was performed using the immunizing peptide in a 
nonmethylated form (E and G) and in a fully methylated form (F and H). 
The antibody was preincubated with the peptide at a final 
concentration of 10  M for 15 min on ice before immunofluorescence 
labeling using SYM10 (E and F) and the snRNP antibody Y12 
(G and H). B and D, E and G, and F and H were double labeled, 
and the cells were visualized by fluorescence microscopy. Bar, 10  M. 
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nucleoplasm but not the nucleolus nor the cytoplasm (Fig. 3
A). To demonstrate the specificity of our antibody for meth-
ylated proteins, we treated HeLa cells with the methylation
inhibitor 5
 
 
 
-deoxy-5
 
 
 
-methylthioadenosine (MTA) for 24 h.
The absence of a signal with the SYM10 antibody after MTA
treatment confirmed that SYM10 was methyl specific (Fig. 3
B). The anti-snRNP antibody Y12 has also been reported to
recognize sDMA-containing Sm proteins (Brahms et al.,
2000). To examine whether the SYM10 antibody staining re-
sembled the snRNPs antibody Y12 staining in HeLa cells,
immunofluorescence was performed on HeLa cells untreated
or treated with MTA. The anti-snRNP antibody Y12 stained
predominantly IGCs, and the signal did not change after
MTA treatment (Fig. 3, C and D). These observations dem-
onstrate that SYM10 is methyl specific and that, at least in
situ, the anti-snRNP antibody Y12 recognizes other non-
methylated epitopes in snRNPs. To confirm the specificity
for sDMA-containing proteins in these experiments, immuno-
fluorescence was performed in the presence of saturating
amounts of the methylated sym10 peptide. Again, only the
SYM10 signal was affected by preincubation with the
sDMA-containing sym10 peptide (Fig. 3, F and H). Preincu-
bation with the unmodified derivative of the sym10 peptide
had no effect on the immunofluorescence signal of either
SYM10 or Y12 (Fig. 3, E and G). These findings demon-
strate that proteins containing sDMA are predominantly nu-
clear and concentrated in bright foci in HeLa cells.
 
Proteins containing sDMA colocalize 
with coilin in Cajal bodies
 
To demonstrate that coilin and SMN colocalize in the cells
used in this study, T4 HeLa cells were immunostained using
a coilin rabbit polyclonal antibody (Andrade et al., 1993)
(Fig. 4 B) and an anti-SMN mAb (Fig. 4 C). The merged
images demonstrate a perfect colocalization within Cajal
bodies (Fig. 4 D). These findings demonstrate that SMN
and coilin colocalize in T4 HeLa cells. Cells were treated
with MTA to examine the effect on SMN and coilin local-
ization. SMN concentrated in a drastically increased number
of bright foci even though the protein levels of SMN did not
change (Fig. 4 G; unpublished data), whereas the localiza-
tion of coilin remained unchanged (Fig. 4 F) and did not ac-
cumulate in the SMN bright foci (Fig. 4 H). Interestingly
Figure 4. SMN colocalizes with 
sDMA-containing proteins in Cajal 
bodies. HeLa cells were labeled for 
immunofluorescence with a coilin 
antibody (B) and a SMN antibody (C). 
Colocalization within Cajal bodies of 
both proteins is shown in the merged 
image (D). HeLa cells treated with MTA 
( MTA) for 24 h were immunostained 
for coilin (F) and SMN (G). HeLa cells 
were labeled for immunofluorescence 
with a coilin mAb (J) and with the 
SYM10 antibody (K). HeLa cells were 
labeled for immunofluorescence with a 
SMN antibody (O) and with SYM10 (N). 
HeLa cells were transfected with myc-
SMN N27 and immunostained using 
the SYM10 antibody (S) and a myc 
antibody (R). The merged image is 
shown in T. Cell nuclei were counter-
stained with DAPI (A, E, I, M, and Q, 
blue). Bars, 10  M. 
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this relocalization of SMN was not observed with another
commonly used methylation inhibitor adenosine-2’,3
 
 
 
-dial-
dehyde (Adox; unpublished data). Upon MTA treatment,
coilin colocalized with SMN in Cajal bodies, but the relocal-
ized SMN accumulated in gems (Fig. 4 H). The change in
SMN localization is most likely due to the lack of binding
partners for SMN.
To confirm that the nuclear foci recognized by SYM10
are Cajal bodies, HeLa cells were costained by using both
SYM10 and anticoilin antibodies. The bright foci stained
by SYM10 colocalized with Cajal bodies as observed with
an anticoilin mAb (Almeida et al., 1998) (Fig. 4, I–L). To
determine whether these bright foci also colocalized with
SMN, HeLa cells were costained using both SYM10 (Fig. 4
N) and an anti-SMN antibody (Fig. 4 O). The nuclear
bodies stained with the SYM10 antibody coincide exactly
with the ones stained with the anti-SMN antibody as
shown in the merged images (Fig. 4 P). To determine
whether SMN influences the localization of sDMA-con-
taining proteins, a dominant-negative mutant of SMN
lacking the first 27 amino acids at the NH
 
2
 
 termini
(SMN
 
 
 
N27 [Pellizzoni et al., 1998]) was transfected in
HeLa cells. Expression of SMN
 
 
 
N27 in HeLa cells resulted
in the apparition of enlarged cytoplasmic and nuclear struc-
tures (Fig. 4 R) as described previously (Pellizzoni et al.,
1998). Interestingly, the nuclear distribution of sDMA-
containing proteins was altered in cells transfected with
SMN
 
 
 
N27 to the enlarged nuclear structures as visualized
by using SYM10 (Fig. 4 S). The nuclear staining observed
with SYM10 is consistent with coilin being a major epitope
in HeLa cells because coilin has been shown to relocalize
with SMN
 
 
 
N27 (Pellizzoni et al., 1998).
 
sDMA-containing proteins localize to IGCs in cells 
containing low levels of SMN
 
Primary fibroblasts are essentially devoid of Cajal bodies,
and coilin is primarily localized diffusely in the nucleoplasm
in these cells (Fig. 5 P) (Spector et al., 1992; Carmo-Fonseca
et al., 1993). To determine the localization of sDMA-con-
taining proteins in cells lacking Cajal bodies, immunofluo-
rescence was performed on WI-38 cells using the snRNPs
antibody Y12 (Fig. 5 A) and the SYM10 antibody (Fig. 5 B).
Both antibodies costained a pattern that was characteristic of
IGCs (Fig. 5 C). Patients with SMA have less SMN protein,
and the severity of the disease inversely correlates with the
number of gems (Coovert et al., 1997). The cellular distri-
bution of sDMA-containing proteins was compared in WI-
38 cells and fibroblasts from a patient with SMA and his un-
affected mother. The unaffected mother derived fibroblast
cells had Sm proteins (Fig. 5 D) and sDMA-containing pro-
Figure 5. The localization of sDMA 
proteins is disrupted in a patient with 
SMA. Human fibroblasts WI-38 were 
doubly stained with Y12 (A) and SYM10 
(B) or an anticoilin antibody (P). 
Fibroblasts from a patient with Werdnig-
Hoffman disease SMA type I, SMN1 / , 
GM03813 (SMA13), and fibroblasts from 
his unaffected mother SMN1 /  
GM03814 (SMA14) were either mock 
treated (DMSO, D–F and J–L) or treated 
with 750  M MTA (G–I and M–O) for
24 h and stained using Y12 (D, G, J
and M) and SYM10 (E, H, K and N).
Fibroblasts from the patient with SMA 
(SMA13) or his unaffected mother 
(SMA14) were treated with DMSO
(Q and S) or treated with 750  M MTA 
(MTA, R and T) for 24 h and stained
using anti-SMN antibodies (Q–S).
Bars, 5  m. 
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teins (Fig. 5 E) colocalizing in IGCs (Fig. 5 F), similar to the
primary fibroblasts WI-38 (Fig. 5, A–C). The cells derived
from the patient with SMA contained Sm proteins localized
within IGCs as observed by using the snRNP antibody Y12
(Fig. 5 J). However, the localization of sDMA-containing
proteins was distinct: sDMA-containing proteins were dis-
tributed in the nucleoplasm as a discrete granular pattern
(Fig. 5 K). Treatment of cells with the methyltransferase in-
hibitor MTA had no effect on the localization of Sm pro-
teins in snRNPs recognized by the antibody Y12 (Fig. 5, G
and M), but the fluorescence signal for SYM10 was reduced
considerably (Fig. 5, H and N). The SMN localization was
examined in cells derived from the SMA patient. The unaf-
fected mother derived cells concentrated SMN in gems
which increased in number after MTA treatment (Fig. 5, Q
compared with R). The SMA patient derived cells did not
concentrate SMN in gems (Fig. 5 S), and treatment of cells
with MTA had no effect on the localization of SMN (Fig. 5
T). These observations suggest that patients with SMA mis-
localize sDMA-containing proteins.
 
The level of PRMT5 and sDMA-containing proteins 
is not affected in the SMA cell line
 
To investigate the levels of PRMT5 protein levels and activity,
lysates from HeLa, WI-38, and SMA cell lines (mother and
affected child) were immunoblotted with an anti-PRMT5 an-
tibody. HeLa cells contained sixfold higher protein levels of
PRMT5 than the three fibroblasts cell lines examined when
normalized to actin by densitometric analysis (Fig. 6 A, lanes
1–4). SMN was elevated in HeLa cells, intermediate in WI-38
and the unaffected SMA mother, and low in the patient with
SMA (Fig. 6 A). HeLa cells contained more total SmB/B
 
 
 
proteins than fibroblasts, but no differences were observed be-
tween normal and affected SMA cell lines when normalized to
actin (Fig. 6 A, lanes 1–4). Anti-PRMT5 immunoprecipitates
followed by in vitro methylation assays using (methyl-
 
3
 
H)
S-adenosyl-
 
L
 
-methionine and GST-SmB
 
 
 
 as an exogenous sub-
strate were performed to assess the levels of PRMT5 activity
between the cell lines. The proteins from the in vitro reactions
were resolved by SDS-PAGE, stained with Coomassie blue
(Fig. 6 B, top), and the methylated proteins were visualized by
Figure 6. The level of PRMT5 and 
sDMA-containing proteins is not 
affected in the SMA cell line. (A) Cell 
lysates from the indicated cell lines were 
immunoblotted with PRMT5, SMN, 
SmB/B’ (ANA128), or actin antibodies. 
The asterisk indicates a nonspecific 
band. (B) PRMT5 immunoprecipitations 
were performed using the indicated cell 
lines. Immunoprecipitated proteins 
were incubated with GST–SmB’ as an 
exogenous substrate in the presence of 
(methyl-
3H)–SAM. Proteins were resolved 
by SDS-PAGE, stained with Coomassie 
blue (top), and visualized by fluorography 
(bottom). The migration of GST–SmB’ 
IgG H and L chains are indicated on the 
right. (C) SYM10 immunoblotting was 
performed on extracts prepared from the 
indicated cell lines. 
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fluorography (Fig. 6 B, bottom). HeLa cells contained higher
levels of PRMT5 activity than the fibroblasts cell lines (Fig. 6
B, lanes 1–4) consistent with higher levels of PRMT5 protein.
However, the levels of sDMA-containing proteins was not
higher in HeLa cells compared with the fibroblasts by using
SYM10 to immunoblot whole cell extracts (Fig. 6 C). Com-
parable levels of methylated coilin were also observed between
the four cell lines (Fig. 6 C, lanes 1–4, see indicated band).
However, qualitative and quantitative differences were ob-
served for some unidentified methylated proteins recognized
by SYM10, including p60 (Fig. 6 C, lanes 1–4, see indicated
bands). Nonetheless, no methylation differences were ob-
served between the mother and the SMA patient (Fig. 6 C,
lanes 3 and 4). These results demonstrate that the distinct lo-
calization of sDMA-containing proteins in SMA patients is
not related to the reduced expression and/or activity of
PRMT5 in these cells. Our results suggest that it is the SMN
protein levels that correlates well with the observed differences
in cellular distribution of sDMA-containing polypeptides.
 
The sDMA-specific antibody SYM10 inhibits 
pre-mRNA splicing
 
To confirm whether sDMA methylated proteins are re-
quired for splicing in vitro
 
,
 
 nuclear extracts were preincu-
Figure 7. Pre-mRNA splicing and spliceosomal formation is impaired in hypomethylated nuclear extracts, and SYM10 inhibits pre-mRNA 
splicing. (A) Splicing reactions were performed by using a 
32P-labeled AdML transcription unit pre-mRNA substrate (2 fmoles) in the presence of 
increasing amount (25–250 ng) of purified antibodies. RNAs were resolved on an 8% denaturing polyacrylamide gel. The positions of 
pre-mRNA and splicing products and intermediates are indicated on the left. (B) DMSO (Mock) or MTA-treated extracts were stained with 
Coomassie blue or immunoblotted with the indicated antibodies. (C) Splicing reactions were performed by using a 
32P-labeled caspase 2 
pre-mRNA. The pre-mRNA transcripts were incubated with either the mock-treated or with the MTA-treated nuclear extracts for increasing 
amount of time. RNAs were resolved on a 6% denaturing polyacrylamide gel. (D) Splicing complexes assembly on the 
32P-labeled adenovirus 
major late transcripts using nuclear extracts that are either mock treated or MTA treated. Heterogeneous (H) and spliceosomal complexes 
(A/B/C) are indicated on the left. 
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bated with an increasing amount of affinity-purified SYM10
antibody. The splicing of radiolabeled adenovirus major late
(AdML) transcripts was assessed (after 2 h), and splicing
products were analyzed by denaturing gel electrophoresis. A
complete inhibition of pre-mRNA splicing was achieved by
the addition of increasing amounts of the SYM10 antibody
(Fig. 7 A, lanes 2–4) but not by normal rabbit serum (Fig. 7
A, lanes 5–7). Preincubation of SYM10 with the methylated
sym10 peptide prevented the inhibition of splicing, showing
the effect is specific (unpublished data). The inhibition of
splicing by SYM10 resembles the inhibition observed with
Y12 (Padgett et al., 1983). However, our immunofluores-
cence results show that Y12 likely recognizes other non-
methylated epitopes. The inhibition observed here with the
SYM10 antibody demonstrates that sDMA-containing pro-
teins are part of the active spliceosome.
Pre-mRNA splicing and spliceosomal complex formation 
are impaired in hypomethylated nuclear extracts
To further confirm whether arginine methylation is a neces-
sary modification for pre-mRNA splicing, nuclear extracts
were prepared from HeLa cells grown in the presence of the
methylation inhibitor MTA. The methylation status of cel-
lular proteins was assessed by using the SYM10 antibody.
More than 90% of the arginine methylation of SmB/B , coi-
lin, and p60 and 75% of the methylation of SmD1 proteins
was lost after treatment as determined by densitometry (Fig.
7 B, lanes 3–4). There was no significant difference in the
level of total proteins (Fig. 7 B, lanes 1–2) and the level of
SmB and SmD proteins in the nuclear extract of mock-
treated and MTA-treated cells (Fig. 7 B, lanes 7–10). Al-
though the immunofluorescent signal with the anti-Y12 an-
tibody did not diminish with MTA (Fig. 3), a reduction in
the level of SmB, B , D, and coilin was observed in MTA-
treated extracts when immunoblotted with Y12 (Fig. 7 B,
lanes 5 and 6). These findings confirm that Y12 recognizes
methylated Sm proteins (Brahms et al., 2000) and a meth-
ylated protein of 80 kD that has been identified recently as
coilin (Hebert et al., 2002).
The splicing of a caspase-2 pre-mRNA substrate (Côté et
al., 2001) was assayed in nuclear extracts prepared from
mock-treated (Fig. 7 C, lanes 1–4) or MTA-treated HeLa
cells (Fig. 7 C, lanes 5–8). Overall splicing efficiency was
reduced twofold in hypomethylated extracts and was most
noticeable by a slower rate of apparition of splicing inter-
mediates: e.g., note the amount of lariat intermediates in
the mock-treated extract after 45 min incubation (Fig. 7 C,
lane 2 compared with 6). A similar inhibition was observed
when using the AdML splicing substrate (unpublished
data). Splicing by hypomethylated extracts was still sensitive
to inhibition by the SYM10 antibody, indicating that the
residual splicing activity is due to the small proportion of
methylated proteins remaining in the extract (unpublished
data). The formation of splicing complexes on the AdML
transcripts was assayed using aliquots of a splicing reaction
performed in mock- or MTA-treated nuclear extracts (Fig.
7 D). After 0, 15, and 45 min of incubation, complexes
were resolved by using native gels. Mock-treated nuclear ex-
tracts supported the formation of normal spliceosomal
complexes (A, B, and C) and heterogeneous (H) complexes
(Fig. 7 D, lanes 2–4 [Konarska and Sharp, 1986]). How-
ever, hypomethylated nuclear extracts showed less conver-
sion into spliceosomal complexes after a 45-min incubation
(Fig. 7 D, lanes 5–7). Moreover, the loading of hnRNPs
onto the pre-mRNA (complex H) was also affected as it mi-
grated slightly faster, suggesting an aberrant composition.
This is consistent with the fact that hnRNPs are a major
class of proteins modified by arginine methylation (Liu and
Dreyfuss, 1995). These studies suggest that normal levels of
sDMA-containing proteins are required to support efficient
pre-mRNA splicing.
Discussion
By using a new sDMA-specific antibody (SYM10), we iden-
tified coilin as an sDMA-containing protein. Immunopre-
cipitated coilin was recognized directly by SYM10 immuno-
blotting, and the in vivo methylation of coilin was further
demonstrated by MALDI-TOF mass spectrometry. Immu-
nofluorescence studies demonstrated that sDMA-containing
proteins are localized diffusely in the nucleoplasm and con-
centrated in Cajal bodies in HeLa cells. Gems were not ob-
served in the untreated T4 HeLa cells used: coilin and SMN
colocalized perfectly in Cajal bodies (Fig. 4). In the presence
of the methylase inhibitor MTA, the appearance of dozens
of gems was observed. Coilin methylation was decreased
with MTA treatment, suggesting that its methylation is nec-
essary to maintain SMN in the Cajal bodies. Primary fibro-
blasts that are devoid of Cajal bodies concentrated sDMA-
containing proteins in IGCs or speckles. Cells derived from
a patient with SMA localized its sDMA-containing proteins
in the nucleoplasm as a discrete granular pattern. SMN may
play a role in localizing sDMA-containing proteins because
the expression of a dominant-negative SMN (SMN N27)
concentrated sDMA-containing proteins in enlarged nuclear
structures rather than Cajal bodies. Moreover, our findings
show that splicing reactions were efficiently inhibited in the
presence of SYM10 antibody and by using hypomethylated
nuclear extracts.
SYM10, a symmetrical 
dimethylarginine-specific antibody
The presence of antibodies that recognize posttranslational
modifications has greatly enhanced our ability to understand
these modifications in vivo (e.g., phosphorylation). The field
of arginine methylation lacks antibodies that can recognize
sDMA-containing polypeptides. The antibody we gener-
ated, SYM10, recognizes sDMA and not aDMA-modified
proteins containing GAR sequences. More specifically, we
have defined that SYM10 requires at least two preferentially
spaced sDMA-G residues for reactivity. This is consistent
with the fact that SYM10 recognized SmB/B  (R
sDMAGGPP-
PPMGR
sDMAG) and SmD1 (9 R
sDMAG repeats), which are
known to contain sDMA in vivo. Furthermore, we show
that the SYM10 epitopes are generated by PRMT5 (Fig. 2),
which is the enzyme thought to methylate symmetrically Sm
proteins (Friesen et al., 2001b; Meister et al., 2001b). The
complete loss of immunostaining with MTA treatment fur-
ther demonstrates that SYM10 also recognizes methylated
epitopes in cells. In contrast, the immunostaining of IGCs is The cellular localization of sDMA-modified proteins | Boisvert et al. 967
not lost by using the anti-snRNP antibody Y12. However,
immunoblotting with Y12 demonstrated that the SmB and
D epitopes were reduced after MTA treatment, demonstrat-
ing that it indeed does recognize methylated epitopes as re-
ported previously (Brahms et al., 2000). The recognition of
many proteins by SYM10 immunoblotting demonstrates
that there exist a plethora of proteins with sDMA.
The Cajal body contains methylated coilin
We show that human coilin arginines 397, 410, 413, and
415 are dimethylated in vivo. These arginines are localized
in GAR regions, which are well known sites of arginine
methylation (Gary and Clarke, 1998). The methylase that
catalyzes this posttranslational modification is unknown,
but is likely to be the PRMT5 methylosome, since the argi-
nines are located within a consensus sequence for PRMT5
(Friesen et al., 2001b; Meister et al., 2001b). The methyla-
tion of coilin may be a signal to rapidly target it to SMN
complexes or vice versa and cause an accumulation in Cajal
bodies (Hebert et al., 2001, 2002). The addition of MTA
but not Adox (unpublished data) relocalized SMN exclu-
sively in gems. It is not known why MTA is the only meth-
ylation inhibitor that causes this redistribution. However,
our observations suggest that methylation regulates the
components of Cajal bodies and regulates the appearance of
gems. Thus, the presence of gems may be a marker for
methylation activity in cells. Our data provide a function
for coilin in the recruitment of Cajal body components. It
is not known whether arginine methylation is regulated,
but coilin may be a protein “sensor” for the levels of
sDMA-containing snRNPs. Thus, it would be the levels of
Sm proteins that would ultimately regulate Cajal body for-
mation as suggested by Sleeman et al. (2001). Thus high
levels of methylated snRNPs such as in rapidly dividing
cells (HeLa) may increase the levels of methylated coilin, re-
sulting in the recruitment of SMN complexes to the Cajal
body for snRNP biogenesis and recycling.
The observation that SYM10 detects proteins within the
nucleus and not the cytoplasm suggest that sDMA is a signal
for nuclear import and that the nuclear import machinery is
tightly coupled to the sDMA-generating methylosome(s) as
proposed by Friesen et al. (2001b) and Meister et al.
(2001b). In agreement with this model, SMN was found re-
cently to be part of a preimport complex containing impor-
tin   , Snurportin, and ZPR1 (Gangwani et al., 2001;
Narayanan et al., 2002), which suggests that SMN may ac-
company newly assembled snRNPs to the nucleus. The ac-
cumulation of SMN in MTA-treated cells is consistent with
the model that SMN functions in snRNP biogenesis or recy-
cling within the nucleus (Pellizzoni et al., 1998). Thus, in
the absence of methylated snRNPs there would be no need
to have SMN in Cajal bodies for snRNP biogenesis, and
SMN would accumulate in a nuclear body, the gem, which
is devoid of snRNPs. Therefore, the presence of gems may
be a reflection of the general absence of methylated proteins.
In this study, three cell types expressing different levels of
SMN protein were used to examine the cellular distribution
of sDMA-containing proteins. The only difference observed
between the cell types was the levels of SMN protein as re-
ported previously (Gangwani et al., 2001). The levels of
SmB protein have been shown to be lower in primary hu-
man fibroblast and may account for the absence of Cajal
bodies in these cells (Sleeman et al., 2001). Indeed, the over-
expression of SmB caused the appearance of Cajal bodies
(Sleeman et al., 2001). In our studies, the levels of SmB and
B  were not significantly lower in the human fibroblasts
compared with HeLa cells. The activity of PRMT5 was
higher in HeLa cells, but this did not appear to affect the
levels of methylated proteins as detected by SYM10 immu-
noblotting. In HeLa cells, the highest SMN-expressing cell
line, sDMA-containing proteins were detected in Cajal bod-
ies and not in IGCs. It is unknown why the IGCs were not
detected, especially since SmB and D proteins are major
epitopes by immunoblotting. A possibility is that meth-
ylated epitopes may be blocked by the presence of SMN that
binds methylated proteins (Friesen et al., 2001a). Thus, the
diffuse nuclear SMN complexes may mask the methylated
proteins in IGCs in HeLa cells. Alternatively SMN may be
involved in the nuclear organization of sDMA-containing
proteins. The argument for this is that the sDMA-contain-
ing proteins of the unaffected mother and the SMA patient
were different. Also consistent with this is the fact that
SMN N27 reorganizes sDMA-containing proteins.
Methylated proteins and SMA
Treatment of the cells derived from the SMA patient with
MTA did not induce gem formation. These data suggest
that the little quantity of SMN that is present in these cells is
not sufficient to concentrate in nuclear foci as detected by
immunofluorescence. Thus, by having lower levels of SMN
the cells have indirectly lost the ability to respond to changes
in the methylation status of their proteins. The presence of
mutations in SMN1 that disrupt association with its RG-
rich substrates (Pellizzoni et al., 1999) suggest that these are
loss of function mutations and would be predicted to also
have mislocalized sDMA-containing proteins. The observa-
tion that the anti-snRNP antibody Y12 stained IGCs in the
SMA patient cells confirmed that the overall organization of
snRNPs is not perturbed. It is interesting that the discrete
granular pattern observed resembles sites of transcription
(Fakan and Nobis, 1978). These findings show that the
lower level of SMN in patients with SMA has a major effect
on the nuclear distribution of methylated proteins.
Arginine methylation and pre-mRNA splicing
Our data suggest that the spliceosomal complexes do not as-
semble properly and may be aberrant in hypomethylated nu-
clear extracts. The two major known components that
would be affected by using methylation inhibitors include
the hnRNPs and the Sm proteins in snRNPs. The aberrant
migration of the H complex observed is consistent with the
observation that hnRNPs are a major family of proteins
modified by arginine methylation (Liu and Dreyfuss, 1995).
Thus methylation may affect their RNA binding activity
and nucleocytoplasmic shuttling capabilities (McBride and
Silver, 2001). The absence of methylation most likely pre-
vents the assembly of snRNPs. Moreover, the absence of
methylation would also prevent the methylation of the
COOH-terminal regions of Sm proteins B and D and may
prevent these proteins from making direct RNA contacts968 The Journal of Cell Biology | Volume 159, Number 6, 2002
with the pre-mRNAs. This is consistent with genetic studies
performed in yeast, demonstrating that the COOH-termi-
nal regions of the Sm proteins B, D1, and D3 are critical for
pre-mRNA splicing and cell viability (Zhang et al., 2001).
However, it is likely that there are other protein components
of the spliceosome that are methylated and this will require
further characterization.
In conclusion, our data show that the methylation of coi-
lin causes SMN to localize in Cajal bodies. In hypometh-
ylated cells, SMN localizes in gems. These findings demon-
strate that arginine methylation regulates gem formation
and is essential to maintain the integrity of the Cajal body.
In addition, our data show that a patient with SMA is un-
able to properly localize its sDMA-containing proteins. We
also show that pre-mRNA splicing reactions require the
presence of sDMA for function.
Materials and methods
Antibodies
SDMA, ADMA, and nonmethylated arginines containing peptides were
synthesized at W.M. Keck Biotech Resource Center. Polyclonal antibodies
were generated by using New Zealand rabbits injected with peptides cou-
pled to keyhole limpet hemocyanin (Sigma-Aldrich). The peptides used for
anti-PRMT5 and anti-SYM10 antibodies were KNRPGPQTRSDLLLS-
GRDWN and KR
sDMAGR
sDMAGR
sDMAGR
sDMAG. SYM10 was affinity purified
(UBI, Upstate). The HA antibody is 12CA5 (Babco). The 9E10 myc anti-
body was from the American Type Culture Collection. The SMN antibody
is from Transduction Laboratories. The Y12 hybridoma was provided
by Robin Reed (Harvard University, Boston, MA). The SmB antibody
(ANA125) and SmB and D antibody (ANA128) are from Cappel. The anti-
body against  -actin is from Sigma-Aldrich. The coilin antibodies were
gifts from Drs. Chan (Scripps Research Institute, La Jolla, CA) and Matera
(Case Western Reserve University, Cleveland, OH).
ELISA
ELISA plates (Costar) were coated with the indicated peptides and
quantitated by using spectrophotometry. The following peptides were
used: sym10
sDMA (KR
sDMAGR
sDMAGR
sDMAGR
sDMAG), SmD3
sDMA
(KAAILKAQVAAR
sDMAGR
sDMAGR
sDMAGMGR
sDMAG), SmD1
sDMA (SRRAS-
VAGR
sDMAGR
sDMAGR
sDMAGR
sDMAGR
sDMAGR
sDMAGR
sDMAGR
sDMAGG), GAR
sDMA
(KFGGR
sDMAGGGR
sDMAGGGR
sDMAGGFGGR
sDMAGGR
sDMAGG), RG-rich
(KGRGRGRGRGPPPPPRGRGRGRG), MBP
sDMA (SRRASVPSQGKGR
sDMA-
GLSLSR), SmD3 (KAAILKAQVAARGRGRGMGRG), GAR
(KFGGR
sDMAGGGR
sDMAGGGR
sDMAGGFGGR
sDMAGGR
sDMAGG), and GAR
aDMA
(KFGGR
aDMAGGGR
aDMAGGGR
aDMAGGFGGR
aDMAGGR
aDMAGG).
DNA constructs
Myc-coilin in pSG5 (Bohmann et al., 1995) was obtained from G. Matera.
SMN N27 was obtained by RT-PCR using HeLa cells RNA.
SiRNA knock-downs
SiRNAs were obtained from Dharmacon Research. PRMT5 siRNA was de-
rived from the PRMT5 sequence (XM_033433) nucleotides 1,598–1,620.
Control siRNA was the Luciferase GL2 duplex (no. D-1120–05; Dharma-
con Research). Cells were washed twice in RMPI   1% Hepes and diluted
to 10
6 cells/ml. 0.5 ml was transferred into 0.4-mm gap electroporation cu-
vettes (Bio-Rad Laboratories) along with 6  g of carrier DNA and 60, 120,
or 240 pmoles of the respective siRNA. Electroporation was 280 V and
950  F. Cells were then incubated at RT for 15 min and replated in com-
plete media. Cells were lysed after 72 h.
Immunofluorescence and protein expression
T4 HeLa cells were cultured directly on coverslips into a 6-well dish (Mad-
don et al., 1986). For drug treatment, cells were incubated for 24 h with
the vehicle (DMSO) or with the methyltransferase inhibitor MTA (Sigma-
Aldrich) at a final concentration of 750  M. Transfection of HeLa cells for
immunofluorescence was achieved using Lipofectamine Plus. Cells were
fixed with 1% paraformaldehyde in 1  PBS at pH 7.4 and permeabilized
with 0.5% Triton X-100 in PBS. The cells were visualized with a Axioplan
fluorescence microscope (Carl Zeiss MicroImaging, Inc.). Immunoprecipi-
tations were performed using 1  g of the respective antibody in a 1% Tri-
ton X-100 lysis buffer as described previously (Bedford et al., 2000).
Mass spectrometry
sDMA-containing proteins were immunopurified from 5   10
8 HeLa cells
using 1 mg of polyclonal SYM10 antibody coupled to 1 g of protein
A–Sepharose (Sigma-Aldrich). After washes, bound proteins were eluted
with the SYM10 peptide. Proteins were resolved by SDS-PAGE and re-
vealed by Coomassie blue staining. The protein bands were excised, in-
gel digested with trypsin, and analyzed by MALDI-TOF on a Voyager DE-
STR mass spectrometer.
Pre-mRNA splicing
HeLa cell nuclear extracts were prepared according to previously estab-
lished protocols and contained  10 mg/ml total proteins. For preparation
of hypomethylated nuclear extracts, HeLa cells in suspension were treated
for 48 h with 250  M MTA followed by a treatment of 24 h with 750  M
MTA. As control, cells were treated with DMSO. AdML (Hernandez and
Keller, 1983; Hardy et al., 1984; Simard and Chabot, 2002) and caspase 2
(Côté et al., 2001) splicing substrates were synthesized using T7 and T3
RNA polymerase (Promega) in the presence of CAP analogue and 
32P– -UTP
from the corresponding DNA templates linearized with BamHI or XhoI, re-
spectively. Splicing reactions were performed essentially as described pre-
viously (Côté et al., 2001). For antibody inhibition of pre-mRNA splicing,
nuclear extracts were preincubated with increasing amount of purified
antibodies as indicated for 10 min on ice before the splicing reaction. 
32P
RNA splicing products were separated on polyacrylamide/urea gels and vi-
sualized by autoradiography.
Electrophoretic separation of splicing complexes
This procedure was adapted from Konarska and Sharp (1986); 4- l ali-
quots were removed from standard splicing reactions at indicated time
points and mixed with 1  l of heparin at 1 mg/ml. 0.5  l of loading buffer
(1  TBE, 20% glycerol, 1% bromophenol blue, and 1% xylene cyanol)
was then added, and the samples were loaded on nondenaturing 4% poly-
acrylamide gels (acrylamide:bisacrylamide   80:1), which had been pre-
electrophoresed at 200 V for 30 min in 50 mM Tris-glycine. Electrophore-
sis was then continued under the same conditions for 4–5 h at RT. The gel
was dried and visualized by autoradiography.
We thank Dave Schriemer (University of Calgary, Alberta, Canada) for the
mass spectrometry analysis. We are grateful to Greg Matera for helpful and
stimulating discussions. We thank Benoit Chabot (Universitè de Sher-
brooke, Sherbrooke, Québec, Canada) Edward Chan, Jane Wu (Washing-
ton University, St. Louis, MO), and Greg Matera for reagents. We acknowl-
edge the National Cell Culture Center for providing HeLaS9 cells.
This work was supported by grant no. 011291 from The National Can-
cer Institute of Canada (NCIC) with funds from the Canadian Cancer Soci-
ety of Canada to S. Richard. J. Côté and F.-M. Boisvert are recipients of a
postdoctoral fellowship and a studentship from the NCIC. F. Bachand is
the recipient of a studentship from the Canadian Institutes of Health Re-
search (CIHR). C. Autexier holds an FRSQ Chercheur-Boursier and a Boeh-
ringer Ingelheim (Canada) Ltd. Young Investigator award with funds from
the CIHR and the Cancer Research Society Inc. S. Richard holds an Investi-
gator award from the CIHR and is a recipient of the Terry Fox Young Inves-
tigator award from the NCIC.
Submitted: 8 July 2002
Revised: 1 November 2002
Accepted: 1 November 2002
References
Almeida, F., R. Saffrich, W. Ansorge, and M. Carmo-Fonseca. 1998. Microinjec-
tion of anti-coilin antibodies affects the structure of coiled bodies. J. Cell
Biol. 142:899–912.
Andrade, L.E.C., E.M. Tan, and E.K.L. Chan. 1993. Immunocytochemical analy-
sis of the coiled body in the cell cycle and during cell proliferation. Proc.
Natl. Acad. Sci. USA. 90:1947–1951.
Baldwin, G.S., and P.R. Carnegie. 1971. Specific enzymic methylation of an argi-
nine in the experimental allergic encephalomyelitis protein from human my-
elin. Science. 171:579–581.
Bedford, M.T., A. Frankel, M.B. Yaffe, S. Clarke, P. Leder, and S. Richard. 2000. The cellular localization of sDMA-modified proteins | Boisvert et al. 969
Arginine methylation inhibits the binding of proline-rich ligands to Src ho-
mology 3, but not WW, domains. J. Biol. Chem. 275:16030–16036.
Bohmann, K., J.A. Ferreira, and A.I. Lamond. 1995. Mutational analysis of p80
coilin indicates a functional interaction between coiled bodies and the nucle-
olus. J. Cell Biol. 131:817–831.
Brahms, H., J. Raymackers, A. Union, F. de Keyser, L. Meheus, and R. Luhrmann.
2000. The C-terminal RG dipeptide repeats of the spliceosomal Sm proteins
D1 and D3 contain symmetrical dimethylarginines, which form a major B-cell
epitope for anti-Sm autoantibodies. J. Biol. Chem. 275:17122–17129.
Brahms, H., L. Meheus, V. de Brabandere, U. Fischer, and R. Luhrmann. 2001.
Symmetrical dimethylation of arginine residues in spliceosomal Sm protein
B/B  and the Sm-like protein LSm4, and their interaction with the SMN
protein. RNA. 7:1531–1542.
Branscombe, T.L., A. Frankel, J.-H. Lee, J.R. Cook, Z.-H. Yang, S. Pestka, and S.
Clarke. 2001. PRMT5 (the Janus-Binding Protein 1) catalyzes the forma-
tion of symmetric dimethylarginine residues in proteins. J. Biol. Chem. 276:
32971–32976.
Burghes, A.H. 1997. When is a deletion not a deletion? When it is converted. Am.
J. Hum. Genet. 61:9–15.
Carmo-Fonseca, M., J. Ferreira, and A.I. Lamond. 1993. Assembly of snRNP-con-
taining coiled bodies is regulated in interphase and mitosis evidence that the
coiled body is a kinetic nuclear structure. J. Cell Biol. 120:841–852.
Chen, D., H. Ma, H. Hong, S.S. Koh, S.M. Huang, B.T. Schurter, D.W. Aswad,
and M.R. Stallcup. 1999. Regulation of transcription by a protein methyl-
transferase. Science. 284:2174–2177.
Coovert, D.D., T.T. Le, P.E. McAndrews, J. Strasswimmer, T.O. Crawford, J.R.
Mendell, S.E. Coulson, E.J. Androphy, T.W. Prior, and A.H.M. Brughes.
1997. The survival motor neuron protein in spinal muscular atrophy. Hum.
Mol. Genet. 6:1205–1214.
Côté, J., S. Dupuis, Z. Jiang, and J.Y. Wu. 2001. Caspase-2 pre-mRNA alternative
splicing: Identification of an intronic element containing a decoy 3  acceptor
site. Proc. Natl. Acad. Sci. USA. 98:938–943.
Eliceiri, G.L., and J.S. Ryerse. 1984. Detection of intranuclear clusters of Sm anti-
gens with monoclonal anti-Sm antibodies by immunoelectron microscopy.
J. Cell. Physiol. 121:449–451.
Fakan, S., and P. Nobis. 1978. Ultrastructural localization of transcription sites
and of RNA distribution during the cell cycle of synchronized CHO cells.
Exp. Cell Res. 113:327–337.
Fakan, S., G. Leser, and T.E. Martin. 1984. Ultrastructural distribution of nuclear
ribonucleoproteins as visualized by immunocytochemistry on thin sections.
J. Cell Biol. 98:358–363.
Fischer, U., Q. Liu, and G. Dreyfuss. 1997. The SMN-SIP1 complex has an essen-
tial role in spliceosomal snRNP biogenesis. Cell. 90:1023–1029.
Frankel, A., N. Yadav, J. Lee, T.L. Branscombe, S. Clarke, and M.T. Bedford.
2001. The novel human protein arginine N-methyltransferase PRMT6 is a
nuclear enzyme displaying unique substrate specificity. J. Biol. Chem. 277:
3537–3543.
Friesen, W.J., S. Massenet, S. Paushkin, A. Wyce, and G. Dreyfuss. 2001a. SMN,
the product of the spinal muscular atrophy gene, binds preferentially to di-
methylarginine-containing protein targets. Mol. Cell. 7:1111–1117.
Friesen, W.J., S. Paushkin, A. Wyce, S. Massenet, G.S. Pesiridis, G. Van Duyne, J.
Rappsilber, M. Mann, and G. Dreyfuss. 2001b. The methylosome, a 20S
complex containing JBP1 and pICln, produces dimethylarginine-modified
Sm proteins. Mol. Cell. Biol. 21:8289–8300.
Gall, J.G. 2000. Cajal bodies: the first 100 years. Annu. Rev. Cell Dev. Biol. 16:
273–300.
Gangwani, L., M. Mikrut, S. Theroux, M. Sharma, and R.J. Davis. 2001. Spinal
muscular atrophy disrupts the interaction of ZPR1 with the SMN protein.
Nat. Cell Biol. 3:376–383.
Gary, J.D., and S. Clarke. 1998. RNA and protein interactions modulated by pro-
tein arginine methylation. Prog. Nucleic Acid Res. Mol. Biol. 61:65–131.
Hardy, S.F., P.J. Grabowski, R.A. Padgett, and P.A. Sharp. 1984. Cofactor re-
quirements of splicing of purified messenger RNA precursors. Nature. 308:
375–377.
Hebert, M., K. Shpargel, J. Ospina, K. Tucker, and A. Matera. 2002. Coilin meth-
ylation regulates nuclear body formation. Dev. Cell. 3:329.
Hebert, M.D., P.W. Szymczyk, K.B. Shparget, and A.G. Matera. 2001. Coilin
forms a bridge between Cajal bodies and SMN, the spinal muscular atrophy
protein. Genes Dev. 15:2720–2729.
Hernandez, N., and W. Keller. 1983. Splicing of in vitro synthesized messenger
RNA precursors in HeLa cell extracts. Cell. 35:89–99.
Konarska, M.M., and P.A. Sharp. 1986. Electrophoretic separation of complexes
involved in the splicing of precursors to mRNAs. Cell. 46:845–855.
Lamond, A.I., and W.C. Earnshaw. 1998. Structure and function in the nucleus.
Science. 280:547–553.
Lee, M.S., M. Henry, and P.A. Silver. 1996. A protein that shuttles between the
nucleus and the cytoplasm is an important mediator of RNA export. Genes
Dev. 10:1233–1246.
Lefebvre, S., L. Burglen, S. Reboullet, O. Clermont, P. Burlet, L. Viollet, B. Beni-
chou, C. Cruaud, P. Millasseau, M. Zeviani, et al. 1995. Identification and
characterization of a spinal muscular atrophy-determining gene. Cell. 80:
155–165.
Lerner, E.A., M.R. Lerner, C.A. Janeway, Jr., and J.A. Steitz. 1981. Monoclonal anti-
bodies to nucleic acid-containing cellular constituents: probes for molecular
biology and autoimmune disease. Proc. Natl. Acad. Sci. USA. 78:2737–2741.
Liu, Q., and G. Dreyfuss. 1995. In vivo and in vitro arginine methylation of RNA
binding proteins. Mol. Cell. Biol. 15:2800–2808.
Liu, Q., and G. Dreyfuss. 1996. A novel nuclear structure containing the survival
of motor neurons protein. EMBO J. 15:3555–3565.
Maddon, P.J., A.G. Dalgleish, J.S. McDougal, P.R. Clapham, R.A. Weiss, and R.
Axel. 1986. The T4 gene encodes the AIDS virus receptor and is expressed
in the immune system and the brain. Cell. 47:333–348.
Matera, A.G. 1999. Nuclear bodies: multifaceted subdomains of the interchroma-
tin space. Trends Cell Biol. 9:302–309.
McBride, A., and P. Silver. 2001. State of the Arg: protein methylation at arginines
comes of age. Cell. 106:5–8.
Meister, G., D. Buhler, R. Pillai, F. Lottspeich, and U. Fischer. 2001a. A multipro-
tein complex mediates the ATP-dependent assembly of spliceosomal U
snRNPs. Nat. Cell Biol. 3:945–949.
Meister, G., C. Eggert, D. Buhler, H. Brahms, C. Kambach, and U. Fischer.
2001b. Methylation of Sm proteins by a complex containing PRMT5 and
the putative U snRNP assembly factor pICln. Curr. Biol. 11:1990–1994.
Melki, J. 1997. Spinal muscular atrophy. Curr. Opin. Neurol. 10:381–385.
Mowen, K.A., J. Tang, W. Zhu, B.T. Schurter, K. Shuai, H.R. Herschman, and
M. David. 2001. Arginine methylation of STAT1 modulates IFN-induced
transcription. Cell. 104:731–741.
Narayanan, U., J.K. Ospina, M.R. Frey, M.D. Hebert, and A.G. Matera. 2002.
SMN, the spinal muscular atrophy protein, forms a pre-import snRNP com-
plex with snurportin1 and importin beta. Hum. Mol. Genet. 11:1785–1795.
Padgett, R.A., S.M. Mount, J.A. Steitz, and P.A. Sharp. 1983. Splicing of messen-
ger RNA precursors is inhibited by antisera to small nuclear ribonucleopro-
tein. Cell. 35:101–107.
Pellizzoni, L., N. Kataoka, B. Charroux, and G. Dreyfuss. 1998. A novel function
for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA
splicing. Cell. 95:615–624.
Pellizzoni, L., B. Charroux, and G. Dreyfuss. 1999. SMN mutants of spinal mus-
cular atrophy patients are defective in binding to snRNP proteins. Proc.
Natl. Acad. Sci. USA. 96:11167–11172.
Pollack, B.P., S.V. Kotenko, W. He, L.S. Izotova, B.L. Barnoski, and S. Pestka.
1999. The human homologue of the yeast proteins Skb1 and Hsl7p interacts
with Jak kinases and contains protein methyltransferase activity. J. Biol.
Chem. 274:31531–31542.
Simard, M.J., and B. Chabot. 2002. SRp30c is a repressor of 3  splice site utiliza-
tion. Mol. Cell. Biol. 22:4001–4010.
Sleeman, J.E., P. Ajuh, and A.I. Lamond. 2001. snRNP protein expression en-
hances the formation of Cajal bodies containing coilin and SMN. J. Cell Sci.
114:4407–4419.
Spector, D.L. 2001. Nuclear domains. J. Cell Sci. 114:2891–2893.
Spector, D.L., G. Lark, and S. Huang. 1992. Differences in snRNP localization be-
tween transformed and nontransformed cells. Mol. Biol. Cell. 3:555–569.
Wang, H., Z.-Q. Huang, L. Xia, Q. Feng, H. Erdjument-Bromage, B.D. Strahl,
S.D. Briggs, C.D. Allis, J. Wong, P. Tempst, and Y. Zhang. 2001. Methyla-
tion of histone H4 at arginine 3 facilitates transcriptional activation by nu-
clear hormone receptor. Science. 293:853–857.
Xu, W., H. Chen, K. Du, H. Asahara, M. Tini, B.M. Emerson, M. Montminy,
and R.M. Evans. 2001. A transcriptional switch mediated by cofactor meth-
ylation. Science. 294:2507–25011.
Yun, C.Y., and X.-D. Fu. 2000. Conserved SR protein kinase functions in nuclear
import and its action is counteracted by arginine methylation in Saccharomy-
ces cerevisiae. J. Cell Biol. 150:707–717.
Zhang, D., A. Nadja, and M. Rosbash. 2001. A biochemical function for the Sm
complex. Mol. Cell. 7:319–329.